Effect of the Administration of L-Carnitine on Body Weight in Women in Crossfit Training

U

University of Guadalajara

Status and phase

Unknown
Phase 2

Conditions

Body Weight Changes

Treatments

Dietary Supplement: Sucralose
Drug: L-Carnitine

Study type

Interventional

Funder types

Other

Identifiers

NCT03436277
LC-CUT-DMHC

Details and patient eligibility

About

The L-carnitine has demonstrated effects in the treatment of obesity mainly promoting the fat degradation during exercise.

Full description

A randomized, double-blind, placebo-controlled clinical trial will be carry out in 24 woman with body mass index ≥ 25 to 29.9 kg/m2. The patients will receive 1.5 g of L-Carnitine deluded in 250 ml of water or placebo before crossfit training, 5 times a week for 8 weeks. Before and after intervention the investigators evaluate: The body composition (body fat, lean body mass), arm muscle circumference, waist circumference, body weight and body mass index.

Enrollment

24 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit).
  • Volunteers with a body mass index equal to or greater than 25 Kg/m2.
  • Volunteers who do not have allergies to L-Carnitine or any of its components.
  • Informed consent signed
  • Women with a recommendation of nutrition two weeks prior to the start of the study.
  • Body weight stable the last 3 months.

Exclusion criteria

  • Volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies.
  • Women with confirmed or suspected pregnancy.
  • Women under lactation and/or puerperium.
  • Hypersensibilility to L-Carnitine or Sucralose.
  • Kown of renal, hepatic or thyroid deseased.
  • Current or previous treatment diet (3 months before inclusion to the study).
  • Current pharmacological treatment for loose body weight or 3 months before inclusion to the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

24 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Sucralose 1,5 g
Treatment:
Dietary Supplement: Sucralose
L-Carnitine
Experimental group
Description:
L- Carnitine 1,5 g
Treatment:
Drug: L-Carnitine

Trial contacts and locations

1

Loading...

Central trial contact

Diana M Hernández, PhD; Tonatiuh González, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems